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Abstract
Background Several Japanese studies have focused on
identifying prognostic factors in patients with positive
lymph nodes to predict recurrence rate and disease-free
survival (DFS). However, different treatment protocol is
followed in Japan compared with the European and
American approach. This study was designed to investigate
whether the number and/or location of lymph nodes pre-
dicts prognosis in patients with DTC treated with total
thyroidectomy, lymph node dissection, and postoperative
radioactive iodine ablation.
Methods All 402 patients who were treated at the
Department of Nuclear Medicine between 1998 and 2010
for DTC were reviewed. Patients were treated with (near)
total thyroidectomy, lymph node dissection on indication,
and postoperative I-131 ablation. Median follow-up was 49
(range, 10–240) months. Outcome measures were recur-
rence rate, disease-free survival, and mean time to
recurrence.
Results Ninety-seven patients had proven lymph node
metastases. Recurrence rate was signiﬁcantly higher in
patients with positive lymph nodes in the lateral compart-
ment vs. patients with lymph node metastasis in the central
compartment (60 vs. 30%, p = 0.007). Disease-free sur-
vival and mean time to recurrence also were signiﬁcantly
shorter (30 vs. 52 months, p = 0.035 and 7 vs. 44 months,
p = 0.004, respectively). The number of lymph nodes and
extranodal growth were not signiﬁcantly associated with
the outcome measures used.
Conclusions The location of positive lymph nodes was
signiﬁcantly correlated with the risk of recurrence and a
shorter DFS. Hence, the TNM criteria are useful in sub-
dividing patients based on risk of recurrence and DFS.
Introduction
Differentiated thyroid cancer (DTC) is the most common
type of thyroid malignancies. The disease-related mor-
tality for DTC is very low, but spread to the regional
lymph nodes frequently occurs, especially in patients with
papillary thyroid cancer [1, 2]. The TNM classiﬁcation [3]
describes the presence of positive cervical lymph nodes
(CLN) as an independent risk factor for recurrence in all
patients older than age 45 years with follicular thyroid
cancer (FTC) and papillary thyroid cancer (PTC). The
disease-related mortality, however, is not inﬂuenced by
this parameter. The TNM classiﬁcation further subdivides
patients with positive lymph nodes into N1a, i.e., positive
nodes in the central compartment (level VI), and N1b
patients, i.e., with positive nodes in the lateral compart-
ment (levels II-IV/V). N1b status in patients with DTC is
thereby implied to result in worse disease-free survival
(DFS).
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related to the location and number of positive lymph nodes
has been done by Ito et al. from Japan [4–7]. One of their
most recent publications implicates that DFS of N1b
patients is only signiﬁcantly lower than that of N1a patients
when: 1) lymph nodes are larger than 3 cm; 2) ﬁve or more
positive lymph nodes are present in the lateral compart-
ment; or 3) extranodal growth is present [5]. The main
problem of applying results of these studies to the Euro-
pean and American population is the different treatment of
patients with DTC in Japan, with a much lower rate of total
thyroidectomies and the limited use of radioactive I-131
therapy. However, European and American guidelines are
primarily based on the results of these Japanese studies
[8, 9]. The purpose of this study was to investigate the
impact of the location and the number of cervical lymph
node metastases on recurrence rate and DFS in patients
with DTC treated in accordance with European/American
standards, with (near) total thyroidectomy and postopera-
tive I-131 ablation.
Patients and methods
We performed a retrospective study in the University
Medical Center Utrecht. All patients referred to our
Nuclear Medicine department for I-131 ablation therapy
after surgical treatment for well-DTC between January
1998 and April 2010 were reviewed (Fig. 1).
Low-risk patients were deﬁned as patients with small
tumors (T1–T2) without the presence of lymph node
metastasis (N0). All other patients were deﬁned as high-
risk patients. This staging is in concordance with the sev-
enth edition of the TNM AJCC staging criteria. Patients
were staged after their initial surgery. Patients were
excluded from analysis when distant metastasis were
present or when the number of positive lymph nodes could
not be determined.
Initial treatment
Patients were treated according to the known extent of
disease at time of diagnosis. All patients were treated by
(near) total thyroidectomy followed by I-131 thyroid
remnant ablation. All patients received an ablative dosage
varying from 3700 to 7400 mBq, 4–6 weeks after thyroid
resection. Patients were not substituted with levothyroxine
in the weeks ahead of ablation therapy to raise endogenous
TSH production. Treatment traditionally consists of sur-
gery followed by radioiodine ablation for every patient
treated for DTC, regardless of size, extension or lymph
node involvement in the Netherlands. Only dosages vary
from 3700 MBq for low-risk patients to 7400 MBq for
patients with distant metastasis.
Preoperative examination consisted of ultrasound of the
neck and thorough physical examination. If enlarged lymph
nodes were detected, a lymph node dissection was per-
formed. Lymph node dissection also was performed based
on operative ﬁndings suggestive of lymph node spread. All
patients who were treated with lateral lymph node resection
also had central neck dissection.
Laboratory analysis and diagnostic whole body scan
Blood samples were obtained at various moments during
follow-up. On the day of administration of the ablative
dosage, blood samples were obtained to measure the levels
of thyroid stimulating hormone (TSH), thyroid hormone,
thyroglobulin (Tg), and thyroglobulin antibodies (Tg-Ab).
Every 6 months, Tg level and Tg-Ab were measured
without TSH stimulation and ultrasound of the neck was
performed to screen for recurrent disease. TSH stimulated
specimen (by LT4 withdrawal or after using intramuscular
rhTSH injections) were drawn at least after 1.4 and 9 years
with the simultaneous performance of a diagnostic whole
body scan using 370 mBq I-131. Tg and TgAb levels were
measured using the DYNOtest Tg-pluS (Brahms Diag-
nostica GmBH, Berlin, Germany). The functional sensi-
tivity for this assay is 0.2 ng/mL.
Additional treatment
Based on ﬁndings during follow-up examination, some
patients received additional treatment. Additional treat-
ment included central (level VI) and/or lateral neck dis-
section (levels II–V), administration of therapeutic dosages
of I-131, and external radiotherapy.
Measures of outcome
For this study, we deﬁned three major measures of out-
come: recurrence of disease, DFS, and mean time to
recurrence. Patients were diagnosed with disease recur-
rence whenever one of the following features was present:
cytological/histological evidence of newly developed dis-
ease, rising Tg or Tg-Ab levels in patients with previously
undetectable levels or detectable Tg/Tg-Ab levels com-
bined with positive ultrasound (cervical lymphadenopa-
thy), diagnostic whole body or posttherapy scintigraphy, or
PET-CT 9-12 months after initial therapy. Some of these
patients already had detectable Tg level, neck ultrasound
suspicious for lymph node recurrence, or uptake on pos-
tablation scan within 9–12 months after therapy and are
therefore better referred to as patients with persistence
disease.
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ing total follow-up, a patient was diagnosed as never free
of disease. DFS was deﬁned as the time in months without
evidence of disease recurrence. Mean time to recurrence
was calculated for all the patients diagnosed with recurrent
disease.
Statistical analysis
Statistical analysis was performed by using SPSS
 for
Windows 15.0 (SPSS, Inc., Chicago, IL). For numeric
variables, Pearson’s chi-squared test was used, whereas
continuous variables were compared by using ANOVA.
The Kaplan–Meier curve was used to compare DFS
rates. p\0.05 was considered to be statistically
signiﬁcant.
Results
As shown in the ﬂowchart, a total of 402 patients with DTC
were reviewed. A total of 97 patients (24%) had a known
number of positive lymph nodes at time of initial diagnosis
without the presence of distant disease and were available
for analysis. Median follow-up was 49 (range, 10–240)
range. Eighty-ﬁve percent of the patients with N1b status
also had lymph node involvement of the central compart-
ment. Patient characteristics are summarized in Table 1.
Forty-ﬁve patients (46%) were diagnosed with recurrent
disease. Most recurrences were of lymphatic origin with
the involvement of regional and/or distant lymph nodes
(83%) One third of the patients were treated with additional
neck dissection, whereas the remaining patients were
treated with one or more additional therapeutic dosages of
Fig. 1 Flowchart of all patients
with DTC
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radiotherapy.
The number of positive lymph nodes was not signiﬁ-
cantly related to the risk of recurrence, DFS, or time until
recurrence for the whole group (Table 2). When analyzing
only the group of patients with N1b status, the number of
lymph nodes also did not signiﬁcantly inﬂuence recurrence
rate (p = 0.308). The only factor that signiﬁcantly inﬂu-
enced recurrence rate and DFS in multivariate analysis was
found to be the presence of positive lymph nodes in the
lateral compartment. Thirty percent of the patients with
positive central lymph nodes developed recurrent disease
compared with 60% of the patients with positive lateral
lymph nodes (p = 0.007).
The mean DFS for N1a patients was 52 versus
30 months for N1b patients (p = 0.035). Also, the mean
time to recurrence was signiﬁcantly shorter in patients with
positive nodes of the lateral compartment (7 vs. 44 months,
p = 0.004, respectively). This difference also applied for
patients with N1b status without the presence of central
lymph nodes (p = 0.023).
All disease-related deaths (n = 4) were observed in the
patients with N1b status; however, this was not statistically
signiﬁcant (p = 0.139), possibly due to the low number of
patients. Results are shown in Table 3; Fig. 2.
Table 1 Patient characteristics of high-risk patients N1M0 (n = 97)
Gender
M 38% (n = 37)
F 62% (n = 60)
Mean age 48 yr (S.D. ± 17)
Histology Papillary: 96%
Follicular: 4%
N stage 1a: 34% (n = 33)
1b: 63% (n = 61)
No. of lymph nodes 1–4: 66% (n = 66)
5–9: 18% (n = 17)
10–14: 7% (n = 7)
15–19: 2% (n = 2)
20–24: 4% (n = 4)
C25: 1% (n = 1)
Mean preablative TSH (±SD) 92 (±41)
Median follow-up (m) 49
Recurrence rate 46% (n = 45)
Disease-related mortality 4% (n = 7)
Table 2 Recurrence rate and
DFS related to the number of
positive lymph nodes
No. of positive
lymph nodes
Total
patients
Recurrence
rate
p value Mean
DFS (mo)
p value Mean time to
recurrence (mo)
p value
\5 66 50% 0.879 37 0.85 16 0.428
[5 31 51% 36 7
\10 83 47% 0.145 37 0.764 15 0.494
[10 14 69% 33 6
\15 90 49% 0.414 38 0.306 14 0.711
[15 7 67% 18 7
Table 3 Recurrence rate and
DFS related to N stage
N
stage
Total
patients
Recurrence
rate
p value Mean
DFS (mo)
p value Mean time to
recurrence (mo)
p value
N1a 33 30% 0.007 52 0.035 44 0.004
N1b 61 60% 30 7
Disease Free Survival (months)
60 50 40 30 20 10 0
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Fig. 2 Kaplan–Meier curve for disease-free survival
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The presence of lymph node spread at the time of diagnosis
predicts a higher risk of recurrent disease for patients with
well-DTC. We found that the location of the lymph nodes
signiﬁcantly inﬂuences recurrence rate, time to recurrence,
and DFS. Patients with clinically evident lymph nodes of
the lateral compartment have a signiﬁcantly higher recur-
rence rate compared with patients with positive central
lymph nodes.
Our research addresses the clinical implication of lymph
node involvement in a European patient group. Most
studies focusing on this subject are from Asia, especially
Japan, where treatment strategy of patients is substantially
different from the European method, whereas European
and American treatment strategy is quite similar.
Results of our study can be used to further specify
treatment and follow-up recommendations for the Euro-
pean and American population. Furthermore, results of
Asian studies are similar, which might indicate that treat-
ment can be performed adequately in different ways for
patients with thyroid cancer.
We also showed that N1b status, in the large majority of
cases,canbeconsideredasmoreadvanceddiseasecompared
with patients with only lymph node spread to the central
compartment. Yet, at the same time our research shows that
patientswiththesolitaryinvolvementoflaterallymphnodes
have a higher recurrence rate and shorter DFS.
Our results are in concordance with the ﬁndings of the
Japanese studies, which found that the presence of clini-
cally evident positive lymph nodes in the lateral compart-
ment was a predictor of higher recurrence rate and shorter
DFS [5, 10, 11].
The number of positive lymph nodes or the presence of
extranodal growth did not contribute signiﬁcantly to a
worse DFS or higher recurrence rate in our study. This is in
contradiction with the results of Ito et al., who found that
the number ([5 positive nodes) and the presence of ex-
tranodal growth did signiﬁcantly inﬂuence DFS. The study
of Lee et al. [12] also investigated the prognostic signiﬁ-
cance of the number of positive nodes, but only in N1a
patients; their preliminary results suggest that more than
ﬁve positive lymph nodes in the central compartment may
affect recurrence rate and DFS. Analysis of our N1a- and
N1b-positive patients did not show a signiﬁcant correlation
between the number of lymph nodes and disease recurrence
(p = 0.549, p = 0.308). Age and extranodal growth also
did not show a signiﬁcant correlation with recurrence rate
(p = 0.165, p = 0.549). Size of the metastatic nodes also
has been indicated as a prognostic factor by Ito et al. and
Sugitani et al. [13]. Our data missed information about the
size of positive lymph nodes and therefore could not be
analyzed regarding this parameter.
Different explanations could exist for the different
ﬁndings between our study and the studies performed in
Asia. The main difference between our study population
and the Japanese population is the nature of the treatment
of thyroid cancer. Whereas routine ablation of the thyroid
remnant is performed in Europe and the United States, it is
not frequently used in Japan and other Asian countries. The
Japanese guidelines for the treatment and follow-up of
thyroid cancer also differ on various other points from the
American and European guidelines [14]. Therefore, the
results of Asian studies, especially about prognostic sig-
niﬁcance, follow-up, and treatment, are sometimes difﬁcult
to generalize to the European and American population.
The use of routine ablation therapy in western countries
might be responsible for the different outcomes in respect to
theprognosticsigniﬁcanceofthenumberandgrowthtypeof
positive lymph nodes between our study and the Japanese
studies. The ablation therapy might compensate for a higher
number of lymph nodes and the presence of extranodal
growth in our patients, neutralizing it as a signiﬁcant prog-
nostic factor. The ablation dosages used in our study varied,
but the current opinion in our institution is that low ablation
dosages are just as effective higher dosages.
Itisquitepossiblethatthenumberoflymphnodesandthe
presence of extranodal growth do inﬂuence recurrence rate
and DFS in the western population, but that our study pop-
ulation was too small to achieve statistical signiﬁcance for
these factors. Japanese treatment, especially lymph node
resection, is performed more often and is usually more
aggressive due to the less frequent use of radioactive iodine.
More information about the lymph nodes is therefore col-
lected and more variables can more easily be analyzed.
Limitations of our study include its retrospective nature.
Randomized and prospective studies are, however, almost
impossible to perform because of the large number of
patients that should be included and the long follow-up
period. In addition, a median follow-up of 49 months for
high-risk patients may be considered relatively short,
because recurrences can occur after 10 years. Even though
most recurrences are identiﬁed in an early stage of disease
(mean time of recurrence in our study was 14 months),
studies with longer follow-up are necessary to support our
ﬁndings. Our study, however, did analyze all patients
treated in an academic institution during the course of more
than 12 years.
With this study, we conﬁrm the adequacy of the seventh
edition of the AJCC Cancer Staging Manual concerning the
subdivision of patients based on lymph node status (N1a
vs. N1b). Other factors, such as the number of positive
lymph nodes or the presence of extranodal growth, could
not be conﬁrmed as prognostic factors that signiﬁcantly
inﬂuence the recurrence rate and DFS in our study
population.
1266 World J Surg (2012) 36:1262–1267
123Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Baek SK, Jung KY, Kang SM et al (2010) Clinical risk factors
associated with cervical lymph node recurrence in papillary
thyroid carcinoma. Thyroid 20(2):147–152
2. Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of
patients with differentiated thyroid carcinoma following initial
therapy. Thyroid 16(12):1229–1242
3. Edge SB (2010) AJCC cancer staging manual, 7th edn. Springer,
New York
4. Ito Y, Tomoda C, Uruno T et al (2005) Ultrasonographically and
anatomopathologically detectable node metastases in the lateral
compartment as indicators of worse relapse-free survival in
patients with papillary thyroid carcinoma. World J Surg 29(7):
917–920. doi:10.1007/s00268-005-7789-x
5. Ito Y, Miyauchi A (2008) Lateral lymph node dissection guided
by preoperative and intraoperative ﬁndings in differentiated
thyroid carcinoma. World J Surg 32(5):729–739. doi:10.1007/
s00268-007-9315-9
6. Ito Y, Fukushima M, Tomoda C et al (2009) Prognosis of patients
with papillary thyroid carcinoma having clinically apparent
metastasis to the lateral compartment. Endocr J 56(6):759–766
7. Ito Y, Tomoda C, Uruno T et al (2004) Preoperative ultrasono-
graphic examination for lymph node metastasis: usefulness when
designing lymph node dissection for papillary microcarcinoma of
the thyroid. World J Surg 28(5):498–501. doi:10.1007/s00268-
004-7192-z
8. Pacini F, Schlumberger M, Dralle H et al (2006) European con-
sensus for the management of patients with differentiated thyroid
carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):
787–803
9. Cooper DS, Doherty GM, Haugen BR et al (2009) Revised
American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid 19(11):1167–1214
10. Ito Y, Higashiyama T, Takamura Y et al (2007) Risk factors for
recurrence to the lymph node in papillary thyroid carcinoma
patients without preoperatively detectable lateral node metastasis:
validity of prophylactic modiﬁed radical neck dissection. World J
Surg 31(11):2085–2091. doi:10.1007/s00268-007-9224-y
11. Ito Y, Miyauchi A, Jikuzono T et al (2007) Risk factors con-
tributing to a poor prognosis of papillary thyroid carcinoma:
validity of UICC/AJCC TNM classiﬁcation and stage grouping.
World J Surg 31(4):838–848. doi:10.1007/s00268-006-0455-0
12. Lee YS, Lim YS, Lee JC et al (2010) Clinical implication of the
number of central lymph node metastasis in papillary thyroid
carcinoma: preliminary report. World J Surg 34(11):2558–2563.
doi:10.1007/s00268-010-0749-0
13. Sugitani I, Kasai N, Fujimoto Y et al (2004) A novel classiﬁca-
tion system for patients with PTC: addition of the new variables
of large (3 cm or greater) nodal metastases and reclassiﬁcation
during the follow-up period. Surgery 135(2):139–148
14. Takami H, Ito Y, Okamoto T et al (2011) Therapeutic strategy for
differentiated thyroid carcinoma in Japan based on a newly
established guideline managed by Japanese Society of Thyroid
Surgeons and Japanese Association of Endocrine Surgeons.
World J Surg 35(1):111–121. doi:10.1007/s00268-010-0832-6
World J Surg (2012) 36:1262–1267 1267
123